WINTON GROUP Ltd Purchases New Position in Moderna, Inc. $MRNA

WINTON GROUP Ltd purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, HoldingsChannel reports. The firm purchased 27,144 shares of the company’s stock, valued at approximately $800,000.

Several other large investors have also made changes to their positions in MRNA. AQR Capital Management LLC bought a new stake in shares of Moderna in the 1st quarter valued at approximately $415,000. NewEdge Advisors LLC grew its stake in shares of Moderna by 732.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after buying an additional 10,185 shares in the last quarter. United Services Automobile Association bought a new stake in shares of Moderna in the 1st quarter valued at approximately $230,000. Focus Partners Wealth grew its stake in shares of Moderna by 58.7% in the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock valued at $668,000 after buying an additional 8,706 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Moderna by 5.2% in the 2nd quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock valued at $1,348,000 after buying an additional 2,410 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $48.40, for a total value of $2,581,462.40. Following the transaction, the president owned 1,477,997 shares of the company’s stock, valued at approximately $71,535,054.80. This trade represents a 3.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,752 shares of company stock valued at $3,453,843 in the last three months. 10.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Jefferies Financial Group set a $37.00 price target on Moderna and gave the company a “hold” rating in a research note on Tuesday, March 3rd. Morgan Stanley set a $33.00 target price on Moderna in a report on Friday, May 1st. Citigroup restated a “neutral” rating on shares of Moderna in a report on Monday, February 16th. Barclays boosted their target price on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a report on Thursday, April 2nd. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $45.00 target price on shares of Moderna in a report on Tuesday, February 17th. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $36.60.

Moderna Stock Down 3.6%

Shares of MRNA stock opened at $45.99 on Thursday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $59.55. The firm has a market cap of $18.25 billion, a PE ratio of -5.64 and a beta of 1.05. The stock has a 50 day moving average of $49.63 and a 200-day moving average of $43.80. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. During the same quarter last year, the firm earned ($2.52) earnings per share. The firm’s quarterly revenue was up 260.2% compared to the same quarter last year. On average, equities analysts predict that Moderna, Inc. will post -6.51 EPS for the current year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.